DigestRedComo funciona
Red
/
Empresas
Ha
No verificado

Harmony Biosciences Holdings, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludWeb y redes sociales

30 Comunicados de prensa

Ver todos los comunicados de prensa
04/03/2026
Eventos
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Harmony Biosciences to Participate in Upcoming Investor Conferences
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
24/02/2026
Web y redes sociales
Telefonía
Mercado de valores
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Sanidad
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
17/02/2026
Industria
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Familia
Infancia
Ir de compras
Medicina - Varios
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
10/02/2026
Biotecnología
Farmacéutica
Salud
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
12/01/2026
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Industria
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
07/01/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Web y redes sociales
Eventos
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
08/12/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
02/12/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
24/11/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Industria
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0
19/11/2025
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
Fuente
Harmony Biosciences Holdings, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0